All In Biotech

Drug Trial Radar · NCT00460512

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,814

Actual

Start

Apr 25, 2007

Primary completion

Jan 22, 2009

Study completion Mar 4, 2020

Sponsor

Lead sponsor
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 16, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with an oral antipsychotic medication.

Conditions

  • Schizophrenia

Interventions

  • Paliperidone ERDrug

    Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least 20 Percent Improvement in Total Positive and Negative Syndrome Scale (PANSS) Score in Those Participants who Transitioned due to Lack of EfficacyTime frame: Endpoint (up to Week 26)
  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint (up to Week 26)Time frame: Baseline and endpoint (up to Week 26)

Locations

231 sites in 22 countries. Site status is shown where the registry gives one.

  • Site not named

    Antwerp, Belgium

  • Site not named

    Bertrix, Belgium

  • Site not named

    Dave, Belgium

  • Site not named

    Diest, Belgium

  • Site not named

    Duffel, Belgium

  • Site not named

    Kortenberg, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Montignies-sur-Sambre, Belgium

  • Site not named

    Mortsel, Belgium

  • Site not named

    Roeselare, Belgium

  • Site not named

    Saint Denijs-Westrem, Belgium

  • Site not named

    Saint-Servais, Belgium

  • Site not named

    Sint-Truiden, Belgium

  • Site not named

    Tielt, Belgium

  • Site not named

    Waregem, Belgium

  • Site not named

    Bulgaria, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Tzerova Korya, Bulgaria

  • Site not named

    Osijek, Croatia

  • Site not named

    Rijeka, Croatia

  • Site not named

    Split, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Elsinore, Denmark

  • Site not named

    Risskov, Denmark

  • Site not named

    Viby J, Denmark

  • Site not named

    Ekenäs, Finland

  • Site not named

    Helsinki, Finland

  • Site not named

    Raahe, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Bar-le-Duc, France

  • Site not named

    Bordeaux, France

  • Site not named

    Bourg-en-Bresse, France

  • Site not named

    Bully-les-Mines, France

  • Site not named

    Caen, France

  • Site not named

    Chambéry, France

  • Site not named

    Clermont-Ferrand, France

  • Site not named

    Créteil, France

  • Site not named

    Dijon, France

  • Site not named

    Dole, France

Showing 40 of 231 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.